Market data not licensed for redistribution.

ENCell

456070 · KOSDAQ · Manufacture of Basic Pharmaceutical Products

– Previous close pending (official data.go.kr feed not active yet) Live price ↗

Source: Financial Services Commission stock price data (data.go.kr), updated once a day.

Daily price, 1 year

Key statistics

Market cap (KRW bn)–

PER–

PBR–

ROE %-70.4

Debt ratio % (liabilities / equity)98

Revenue TTM (KRW bn)4.2

Op. profit TTM (KRW bn)-18.2

Dividend yield %–

Basis: market cap at …; equity = total equity (consolidated if available) at 2026.06.30; net income = trailing 12 months to 2026.06.30 (separate). PER is not shown when TTM net income is negative.

Upcoming risk events

Next 90 days for this company, plus macro events tagged with this ticker or its sector. Not a recommendation.

2026-12-12

Convertible bonds (CB): conversion / exercise period starts ↗

12.62% of shares · price ₩14,295 · refix floor ₩11,436 (80.0%) · size ₩22.5bn

High

See it in the full calendar →

Annual results (KRW bn)

	2021	2022	2023	2024	2025
Revenue	–	–	–	7.2	5.3
Operating profit	–	–	–	-15.7	-17.9
Net income	–	–	–	-15.2	-16.1

Quarterly results (KRW bn, 3 months)

	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	1.1	1.2	1.5	1.4	0.3	0.9
Operating profit	-4.8	-4.5	-3.7	-4.9	-4.9	-4.7
Net income	-4.6	-4.3	-3.6	-3.5	-5.3	-7.2

Largest shareholder

As of the 2025 annual report: 장종욱 and related parties hold 18.28% of common shares.

Recent disclosures

Date	Filing
2026-08-27	Insider / major-holder ownership report 주식등의대량보유상황보고서(일반)	DART original
2026-08-24	Insider / major-holder ownership report 주식등의대량보유상황보고서(일반)	DART original
2026-08-14	Periodic report (annual/half/quarterly) 반기보고서 (2026.06)	DART original
2026-07-13	CB conversion / price adjustment 전환가액의조정 (제1회차)	DART original
2026-07-10	Clinical trial / regulatory approval [기재정정]투자판단관련주요경영사항(임상시험계획변경승인) (샤르코마리투스(CharcotMarieTooth disease, CMT) 1A형 환자를 대상으로 EN001의 유효성 및 안전성을 평가하기 위해 1b/2a상 임상시험계획 변경승인)	DART original
2026-06-25	Insider / major-holder ownership report 임원ㆍ주요주주특정증권등소유상황보고서	DART original
2026-06-24	Insider / major-holder ownership report 임원ㆍ주요주주특정증권등소유상황보고서	DART original
2026-06-24	Insider / major-holder ownership report 임원ㆍ주요주주특정증권등소유상황보고서	DART original
2026-06-24	Insider / major-holder ownership report 임원ㆍ주요주주특정증권등소유상황보고서	DART original
2026-06-02	IR event 기업설명회(IR)개최	DART original
2026-06-01	Single sales/supply contract [기재정정]단일판매ㆍ공급계약체결	DART original
2026-05-20	Insider / major-holder ownership report 임원ㆍ주요주주특정증권등소유상황보고서	DART original

Past material filings and price reaction (market-adjusted)

Date	Filing type	On the news (vs. market)	Next day (vs. market)	20 days (vs. market)
2026-04-20	Single sales/supply contract	+1.8%	-3.9%	-22.0%
2026-03-20	Clinical trial / regulatory approval	-0.8%	+1.9%	+2.0%
2026-03-17	Clinical trial / regulatory approval	+7.0%	-8.6%	-11.2%
2026-02-03	Clinical trial / regulatory approval	+0.4%	-2.8%	-11.9%
2026-01-08	Clinical trial / regulatory approval	+9.9%	-7.6%	-25.7%
2025-12-04	Convertible bond issuance	+3.7%	+2.8%	-1.2%
2025-11-17	Clinical trial / regulatory approval	-0.5%	-2.9%	+13.2%
2025-08-18	Clinical trial / regulatory approval	-2.2%	-2.2%	-0.0%
2025-07-03	Single sales/supply contract	+5.0%	-0.6%	-6.9%
2025-05-28	Single sales/supply contract	+1.1%	-0.7%	-14.6%

For information only, not investment advice. Data may be delayed or inaccurate. Full disclaimer → Data: OpenDART (FSS), stock prices: official previous-day close from the Financial Services Commission (data.go.kr) and FinanceData/marcap history, index data via FinanceDataReader, FX: ECB reference rates, crypto data from Upbit, Bithumb and Binance public APIs.
Market data not licensed for redistribution.
© Crypvu · Crypto market view